Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Matteo Libero Baroni, Diego Sánchez‐Martínez, Francisco Gutiérrez Agüera, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000845-e000845
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang, Lingling Zhu, Hui Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 223
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
Martin Wermke, Sabrina Kraus, Armin Ehninger, et al.
Blood (2021) Vol. 137, Iss. 22, pp. 3145-3148
Open Access | Times Cited: 121
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
David A. Sallman, Tessa Kerre, Violaine Havelange, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 3, pp. e191-e202
Closed Access | Times Cited: 58
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Sascha Haubner, Jorge Mansilla‐Soto, Sarah Nataraj, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1871-1891.e6
Open Access | Times Cited: 48
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Nadia El Khawanky, Amy Hughes, Wenbo Yu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 78
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Simona Caruso, Biagio De Angelis, Francesca Del Bufalo, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 62
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 47
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
Diego Sánchez‐Martínez, Néstor Tirado, Sofia Mensurado, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e005400-e005400
Open Access | Times Cited: 39
Inhibitory CARs fail to protect from immediate T cell cytotoxicity
Maximilian A. Funk, Gerwin Heller, Petra Waidhofer‐Söllner, et al.
Molecular Therapy (2024) Vol. 32, Iss. 4, pp. 982-999
Open Access | Times Cited: 13
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Zhaoyun Liu, Wenhui Lei, Hao Wang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of “On-Target, Off-Tumor Toxicity”
Yinyin Zhang, Yingmei Li, Weijie Cao, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 42
CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
Xin Jin, Danni Xie, Rui Sun, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Romina Marone, Emmanuelle Landmann, Anna Devaux, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 12
Open Access | Times Cited: 21
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
Andrew D.J. Pearson, Claudia Rössig, Crystal L. Mackall, et al.
European Journal of Cancer (2021) Vol. 160, pp. 112-133
Open Access | Times Cited: 33
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
Michael Boettcher, Alexander Joechner, Ziduo Li, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2158-2158
Open Access | Times Cited: 25
Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
Jan Koedam, Martin Wermke, Armin Ehninger, et al.
Current Opinion in Hematology (2022) Vol. 29, Iss. 2, pp. 74-83
Open Access | Times Cited: 23
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
Samanta Romina Zanetti, Talía Velasco-Hernández, Francisco Gutiérrez‐Agüera, et al.
Molecular Therapy (2021) Vol. 30, Iss. 2, pp. 550-563
Open Access | Times Cited: 31
Worked to the bone: antibody-based conditioning as the future of transplant biology
James M. Griffin, Fiona Healy, Lekh N. Dahal, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 22
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
Vincenzo Maria Perriello, Maria Caterina Rotiroti, I. Pisani, et al.
Blood Advances (2022) Vol. 7, Iss. 12, pp. 2855-2871
Open Access | Times Cited: 21
Immune therapy: a new therapy for acute myeloid leukemia
Chen Tian, Zehui Chen
Blood Science (2022) Vol. 5, Iss. 1, pp. 15-24
Open Access | Times Cited: 17
Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation
Reni Kitte, Robert Serfling, Ulrich Blache, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 965-965
Open Access
In-depth analysis of the safety of CAR-T cell therapy for solid tumors
Jiayi Dong, Jun Wu, Jin Ye, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
LILRB1-directed CAR-T cells for the treatment of hematological malignancies
Katsiaryna Marhelava, Klaudyna Fidyt, Monika Pępek, et al.
Leukemia (2025)
Open Access
Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia
Yang Liu, Wanting Wang, Chaofan Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top